The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1

Biochemical Pharmacology

Volumn 74, Issue 7, 2007, Pages 1050-1056

  Stenfeldt, A L ^a,b   Karlsson, J ^a   Wenneras C ^b,c   Bylund, J ^a   Fu, H ^a   Dahlgren, C ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Formyl peptide receptor; Formyl peptide receptor like 1; Inhibitor; Neutrophil; Non steroidal anti inflammatory drug; Piroxicam

Indexed keywords

CALCIUM; FLUORESCENT DYE; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SUPEROXIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIGAND BINDING; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR BINDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; NEUTROPHILS; OLIGOPEPTIDES; PIROXICAM; PROTEIN BINDING; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SUPEROXIDES;

EID: 34548041876     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.049     Document Type: Article

References (34)

1. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231 (1971) 232-235
2. Vane J.R., and Botting R.M. Mechanism of action of antiinflammatory drugs. Int J Tissue React 20 (1998) 3-15
3. Pouliot M., Gilbert C., Borgeat P., Poubelle P.E., Bourgoin S., Creminon C., et al. Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils. FASEB J 12 (1998) 1109-1123
4. Kim J.S., Kim J.M., Jung H.C., and Song I.S. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci 46 (2001) 2277-2284
5. Colli S., Colombo S., Tremoli E., Stragliotto E., and Nicosia S. Effects of tenoxicam on superoxide anion formation, beta-glucuronidase release and fMLP binding in human neutrophils: comparison with other NSAIDs. Pharmacol Res 23 (1991) 367-379
6. Minta J.O., and Williams M.D. Some nonsteroidal antiinflammatory drugs inhibit the generation of superoxide anions by activated polymorphs by blocking ligand-receptor interactions. J Rheumatol 12 (1985) 751-757
7. Neal T.M., Vissers M.C., and Winterbourn C.C. Inhibition by nonsteroidal anti-inflammatory drugs of superoxide production and granule enzyme release by polymorphonuclear leukocytes stimulated with immune complexes or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol 36 (1987) 2511-2517
8. Boulay F., Tardif M., Brouchon L., and Vignais P. Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem Biophys Res Commun 168 (1990) 1103-1109
9. Ye R.D., Cavanagh S.L., Quehenberger O., Prossnitz E.R., and Cochrane C.G. Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem Biophys Res Commun 184 (1992) 582-589
10. Fu H., Bylund J., Karlsson A., Pellme S., and Dahlgren C. The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8. Immunology 112 (2004) 201-210
11. Rabiet M.J., Huet E., and Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol 35 (2005) 2486-2495
12. Betten A., Dahlgren C., Hermodsson S., and Hellstrand K. Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met. Scand J Immunol 58 (2003) 321-326
13. Tuluc F., Meshki J., and Kunapuli S.P. Membrane lipid microdomains differentially regulate intracellular signaling events in human neutrophils. Int Immunopharmacol 3 (2003) 1775-1790
14. Fu H., Bjorkman L., Janmey P., Karlsson A., Karlsson J., Movitz C., et al. The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide. BMC Cell Biol 5 (2004) 50
15. Dahlgren C., and Karlsson A. Respiratory burst in human neutrophils. J Immunol Methods 232 (1999) 3-14
16. Partida-Sanchez S., Cockayne D.A., Monard S., Jacobson E.L., Oppenheimer N., Garvy B., et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med 7 (2001) 1209-1216
17. Waller A., Sutton K.L., Kinzer-Ursem T.L., Absood A., Traynor J.R., Linderman J.J., et al. Receptor binding kinetics and cellular responses of six N-formyl peptide agonists in human neutrophils. Biochemistry 43 (2004) 8204-8216
18. Angelis-Stoforidis P., Vajda F.J., and Christophidis N. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on human polymorphonuclear leucocyte function in buffer and plasma. Clin Exp Rheumatol 16 (1998) 703-708
19. Christophe T., Karlsson A., Dugave C., Rabiet M.J., Boulay F., and Dahlgren C. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem 276 (2001) 21585-21593
20. Karlsson J., Fu H., Boulay F., Bylund J., and Dahlgren C. The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists. Biochem Pharmacol 71 (2006) 1488-1496
21. Lazzari K.G., Proto P., and Simons E.R. Neutrophil hyperpolarization in response to a chemotactic peptide. J Biol Chem 265 (1990) 10959-10967
22. Sklar L.A., Fay S.P., Seligmann B.E., Freer R.J., Muthukumaraswamy N., and Mueller H. Fluorescence analysis of the size of a binding pocket of a peptide receptor at natural abundance. Biochemistry 29 (1990) 313-316
23. Dahlgren C., Christophe T., Boulay F., Madianos P.N., Rabiet M.J., and Karlsson A. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor. Blood 95 (2000) 1810-1818
24. Fu H., Karlsson J., Bylund J., Movitz C., Karlsson A., and Dahlgren C. Ligand recognition and activation of formyl peptide receptors in neutrophils. J Leukoc Biol 79 (2006) 247-256
25. Schiffmann E., Corcoran B.A., and Wahl S.M. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci USA 72 (1975) 1059-1062
26. Gao J.L., Becker E.L., Freer R.J., Muthukumaraswamy N., and Murphy P.M. A high potency nonformylated peptide agonist for the phagocyte N-formylpeptide chemotactic receptor. J Exp Med 180 (1994) 2191
27. Hawkey C.J. COX-2 inhibitors. Lancet 353 (1999) 307-314
28. Kaplan H.B., Edelson H.S., Korchak H.M., Given W.P., Abramson S., and Weissmann G. Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo. Biochem Pharmacol 33 (1984) 371-378
29. Gekle J.M., Rescek D.M., and Whipple E.B. Zwitterionic piroxicam in polar solution. Magn Reson Chem 27 (1989) 150-154
30. Edelson H.S., Kaplan H.B., Korchak H.M., Smolen J.E., and Weissmann G. Dissociation by piroxicam of degranulation and superoxide anion generation from decrements in chlortetracycline fluorescence of activated human neutrophils. Biochem Biophys Res Commun 104 (1982) 247-253
31. Abramson S.B., Leszczynska-Piziak J., Clancy R.M., Philips M., and Weissmann G. Inhibition of neutrophil function by aspirin-like drugs (NSAIDS): requirement for assembly of heterotrimeric G proteins in bilayer phospholipid. Biochem Pharmacol 47 (1994) 563-572
32. Perez H.D., Holmes R., Vilander L.R., Adams R.R., Manzana W., Jolley D., et al. Formyl peptide receptor chimeras define domains involved in ligand binding. J Biol Chem 268 (1993) 2292-2295
33. Quehenberger O., Prossnitz E.R., Cavanagh S.L., Cochrane C.G., and Ye R.D. Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem 268 (1993) 18167-18175
34. Czapiga M., Gao J.L., Kirk A., and Lekstrom-Himes J. Human platelets exhibit chemotaxis using functional N-formyl peptide receptors. Exp Hematol 33 (2005) 73-84